New treatments for myasthenia: A focus on antisense oligonucleotides

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 13-17

  Angelini, Corrado ^a   Martignago, Sara ^b   Bisciglia, Michela ^b  

^a IRCCS SAN CAMILLO HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Acetyl cholinesterase; Antisense oligonucleotides; EN101; Myasthenia gravis

Indexed keywords

ACETYLCHOLINESTERASE; ANTISENSE OLIGONUCLEOTIDE; CHOLINESTERASE INHIBITOR; DYFLOS; EN 101; IMMUNOMODULATING AGENT; MONARSEN; PYRIDOSTIGMINE; STEROID; UNCLASSIFIED DRUG;

ACETYLCHOLINESTERASE GENE; ALTERNATIVE RNA SPLICING; ARTICLE; AUTOIMMUNITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXON; FOLLOW UP; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MYASTHENIA GRAVIS; NONHUMAN; UNSPECIFIED SIDE EFFECT;

ACETYL CHOLINESTERASE; ANTISENSE OLIGONUCLEOTIDES; EN101; MYASTHENIA GRAVIS;

ACETYLCHOLINESTERASE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; MYASTHENIA GRAVIS; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN ISOFORMS; RECEPTORS, CHOLINERGIC;

EID: 84872343234     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S25716     Document Type: Article

References (25)

1. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25): 1797-1810.
2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptors antibodies. Net Med. 2001;7(3):365-368.
3. Hughes B W, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction. Muscle Nerve. 2006;33(4):445-461.
4. Howard JF Jr, editor. Myasthenia Gravis: A Manual for the Health Care Provider. St Paul, MN: Myastehia Gravis Foundation of America; 2008. Available from: http://www.myasthenia.org/LinkClick.aspx?fleticket=S472fPAE1ow%3D&tabid=69. Accessed November 18, 2008.
5. Meshorer E, Toiber D, Zurel D, et al. Combinatorial complexity of 5 alternative acetylcholinesterase transcripts and protein products. J Biol Chem. 2004;279:29740-29751.
6. Meshorer E, Bryk B, Toiber D, et al. SC35 promotes sustainable stress-induced alternative splicing of neuronal acetylcholinesterase mRNA. Mol Psychiatry. 2005;10:985-997.
7. Meshorer E, Soreq H. Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends Neurosci. 2006;29(4): 216-224.
8. Massoulié J. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals. 2002;11:130-143.
9. Li Y, Camp S, Rachinsky TL, Getman D, Taylor P. Gene structure of mammalian acetylcholinesterase. Alternative exons dictate tissue-specifc expression. J Biol Chem. 1991;266:23083-23090.
10. Seidman S, Sternfeld M, Ben Aziz-Aloya R, Timberg R, Kaufer-Nachum D, Soreq H. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 3′-terminal exons. Mol Cell Biol. 1995;15:2993-3002.
11. Kaufer D, Soreq H. Tracking cholinergic pathways from psychological and chemical stressors to variable neurodeterioration paradigms. Curr Opin Neurol. 1999;12:739-743.
12. Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 2003;17:214-222.
13. Lev-Lehman E, Evron T, Broide RS, et al. Synaptogenesis and myopathy under acetylcholinesterase overexpression. J Mol Neurosci. 2000;14:93-105.
14. Schwarz M, Loewenstein-Lichtenstein Y, Glick D, Liao J, Norgaard-Pedersen B, Soreq H. Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants. Brain Res Mol Brain Res. 1995;31:101-110.
15. Kaufer D, Friedman A, Seidman S, Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature. 1998;393: 373-377.
16. Sussman JD, Argov Z, McKee D, Hazum E, Brawer S, Soreq H. Antisense treatment for myasthenia gravis: experience with monarsen. Ann N Y Acad Sci. 2008;1132:283-290.
17. Dori A, Soreq H. Neuromuscular therapeutics by RNA-targeted suppression of ACHE gene expression. Ann N Y Acad Sci. 2006;1082: 77-90.
18. Soreq H, Seidman S. Acetylcholinesterase - new roles for an old actor. Nat Rev Neurosci. 2001;2:294-302.
19. Soreq H, Ben-Aziz R, Prody CA, et al. Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G + C-rich attenuating structure. Proc Natl Acad Sci U S A. 1990;87: 9688-9692.
20. Evron T, Moyal-Segal LB, Lamm N, Geffen A, Soreq H. RNA-targeted suppression of stress-induced allostasis in primate spinal cord neurons. Neurodegener Dis. 2005;2(1):16-27.
21. Pollak Y, Gilboa A, Ben-Menachem O, Ben-Hur T, Soreq H, Yirmiya R. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann Neurol. 2005;57(5):741-745.
22. Amarin: RNA therapy results announced to attract suitors [opinion]. PharmaWatch: Monthly Review. 2009;8(7):27-28.
23. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic infammatory response to endotoxin. Nature. 2000;405:458-462.
24. Huang D, Shi FD, Giscombe R, Zhou Y, Ljunggren HG, Lefvert AK. Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis. Eur J Immunol. 2001;31:225-232.
25. Martignago S, Fanin M, Albertini E, Pegoraro E, Angelini C. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol. 2009;35(1):103-110.